Amphastar Pharmaceuticals Inc. (AMPH)

Market Closed

16 Oct, 08:00 PM

NASDAQ (NGS)

25. 87

-0.55

-2.0818%

1.17B Market Cap

- P/E Ratio

- Div Yield

352,100 Volume

- Eps

$ 26.42

Previous Close

Investors:

+29

Add Transaction

Day Range

25.52 26.61

Year Range

16.65 29.52

Want to track AMPH and more in your Portfolio? 🎯

Get Started For Free

Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 week ago

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

Zacks | 1 month ago

New Strong Sell Stocks for August 14th

AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.

Zacks | 2 months ago

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Seekingalpha | 2 months ago

Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 2 months ago

Amphastar Pharmaceuticals Q2 Earnings Call Highlights

Amphastar Pharmaceuticals NASDAQ: AMPH reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations.

Marketbeat | 2 months ago

New Strong Sell Stocks for June 23rd

ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.

Zacks | 3 months ago

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals NASDAQ: AMPH is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors at the East Coast IDEAS Conference.

Marketbeat | 4 months ago

Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag

Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.